Funding for this research was provided by:
National Institutes of Health (R01 AI119145, F30 AI122673, KL2TR001435, S10OD018522, S10OD026880)
New York State Department of Health (Empire Clinical Research Investigator Program)
Received: 4 June 2020
Accepted: 2 November 2020
First Online: 16 November 2020
Ethics approval and consent to participate
: The study protocols were reviewed and approved by the Icahn School of Medicine at Mount Sinai Institutional Review Board for the collection and bacterial genome sequencing of discarded clinical bacteremia specimens by the Pathogen Surveillance Program (protocol HS# 13-00981) and chart reviews of outbreak cases and non-outbreak controls (protocol HS# 17-02246), as defined by DHHS regulations. A waiver of authorization for use and disclosure of protected health information (PHI) and a waiver of informed consent were approved for both protocols based on the criteria that the use or disclosure of PHI involved no more than minimal risk to the privacy of individuals and because the research could not practically be conducted without the waiver and without access to and use of the PHI. The research conformed to the principles of the Helsinki Declaration.
: Not applicable.
: Robert Sebra is VP of Technology Development and a stockholder at Sema4, a Mount Sinai Venture. This work, however, was conducted solely at the Icahn School of Medicine at Mount Sinai. The remaining authors declare that they have no competing interests.